Predicted Trait | |
Reported Trait | Diastolic blood pressure |
Mapped Trait(s) | diastolic blood pressure (EFO_0006336) |
Additional Trait Information | Used to predict apparent treatment-resistant hypertension |
Score Construction | |
PGS Name | DBP_PRS |
Development Method | |
Name | PRS-CS |
Parameters | p - value threshold, 1e-1 |
Variants | |
Original Genome Build | hg19 |
Number of Variants | 1,119,054 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000270 |
Citation (link to publication) | Breeyear JH et al. Circ Genom Precis Med (2022) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST007268 Europe PMC: 30578418 |
365,998 individuals | European | MVP, UKB |
GWAS Catalog: GCST007268 Europe PMC: 30578418 |
63,490 individuals | African unspecified | MVP, UKB |
GWAS Catalog: GCST007268 Europe PMC: 30578418 |
22,802 individuals | Hispanic or Latin American | MVP, UKB |
GWAS Catalog: GCST007268 Europe PMC: 30578418 |
4,792 individuals | Asian unspecified | MVP, UKB |
GWAS Catalog: GCST007268 Europe PMC: 30578418 |
2,695 individuals | Native American | MVP, UKB |
GWAS Catalog: GCST004386 Europe PMC: 28498854 |
31,155 individuals | African unspecified | NR |
GWAS Catalog: GCST005978 Europe PMC: 29403010 |
136,615 individuals | East Asian | BBJ |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
— | 341,930 individuals, 45.0 % Male samples |
European | UKB | — | Mean = 56.64 years | — | Multi-Ancestry | — |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM012728 | PSS009510| Ancestry Not Reported| 4,407 individuals |
PGP000270 | Breeyear JH et al. Circ Genom Precis Med (2022) |
Reported Trait: Apparent Treatment-Resistant Hypertension | OR: 1.06 [1.01, 1.11] | AUROC: 0.681 [0.669, 0.686] | — | age, age^2, bmi, sex, top 10 principal components of ancestry | — |
PPM012726 | PSS009511| African Ancestry| 10,052 individuals |
PGP000270 | Breeyear JH et al. Circ Genom Precis Med (2022) |
Reported Trait: Apparent Treatment-Resistant Hypertension | OR: 1.04 [0.94, 1.16] | AUROC: 0.663 [0.644, 0.688] | — | age, age^2, bmi, sex, top 10 principal components of ancestry | — |
PPM012727 | PSS009512| European Ancestry| 57,090 individuals |
PGP000270 | Breeyear JH et al. Circ Genom Precis Med (2022) |
Reported Trait: Apparent Treatment-Resistant Hypertension | OR: 1.05 [1.01, 1.11] | AUROC: 0.679 | — | age, age^2, bmi, sex, top 10 principal components of ancestry | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS009511 | Apparent Treatment-Resistant Hypertension | — | [ ,
37.0 % Male samples |
Mean = 50.6 years | African American or Afro-Caribbean | African American, Non-Hispanic Black | BioVU | — |
PSS009511 | Apparent Treatment-Resistant Hypertension | — | [ ,
37.0 % Male samples |
Mean = 50.6 years | African American or Afro-Caribbean | African American, Non-Hispanic Black | BioVU | Multi-Ancestry analysis |
PSS009512 | Apparent Treatment-Resistant Hypertension | — | [ ,
46.0 % Male samples |
Mean = 58.58 years | European | European, Non-Hispanic White | BioVU | — |
PSS009512 | Apparent Treatment-Resistant Hypertension | — | [ ,
46.0 % Male samples |
Mean = 58.58 years | European | European, Non-Hispanic White | BioVU | Multi-Ancestry analysis |
PSS009510 | Apparent Treatment-Resistant Hypertension | — | [
|
— | Not reported | — | BioVU | Multi-Ancestry analysis |